We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CyBorD induction therapy in clinical practice.
- Authors
Areethamsirikul, N; Masih-Khan, E; Chu, C-M; Jimenez-Zepeda, V; Reece, D E; Trudel, S; Kukreti, V; Tiedemann, R; Chen, C
- Abstract
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in a limited number of patients, its high efficacy and ease of administration have led to its widespread use. Given that clinical trial efficacy can overestimate real-life effectiveness, we reviewed our institutional experience with 109 newly diagnosed patients who were treated with CyBorD in a non-clinical trial setting. After a median of four cycles, overall response rate (ORR) and very good partial response rate or better (⩾VGPR) were 95 and 66%, respectively, comparable to phase 2 studies of CyBorD and other three/four-drug induction regimens. All patients subsequently underwent successful stem cell collection and upgraded responses to ORR 98% and ⩾VGPR 79% post transplant. At a median follow-up of 19.8 months after diagnosis, the 2-year OS probability was 95.3% (95%CI: 89-98). The presence of concurrent plasmacytoma at diagnosis was the only prognostic factor predicting poorer survival (HR=5.56; 95%CI: 0.92-33.74; P=0.03). CyBorD was well-tolerated, with no severe peripheral neuropathy and minimal hematologic toxicity. Therefore, CyBorD is a convenient, well-tolerated, highly effective induction regimen in preparation for autologous SCT in real-life clinical practice.
- Subjects
BORTEZOMIB; DEXAMETHASONE; CYCLOPHOSPHAMIDE; DRUG efficacy; PLASMACYTOMA; DIAGNOSIS
- Publication
Bone Marrow Transplantation, 2015, Vol 50, Issue 3, p375
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2014.288